B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ACVR1B

MOLECULAR TARGET

activin A receptor type 1B

UniProt: P36896NCBI Gene: 9125 compounds

ACVR1B (activin A receptor type 1B) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ACVR1B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1sb 2035804.92136
2doramapimod4.0657
3sb 2021903.6437
4nintedanib3.6136
5tae 6843.4330
6fedratinib3.4029
7saracatinib3.3327
8sb 4315423.3327
9dabrafenib3.3026
10dorsomorphin3.1422
11at 92833.0921
12lestaurtinib3.0420
13danusertib2.9418
14galunisertib2.9418
15r 4062.8316
16k 252a2.8316
17cediranib2.8316
18mk 51082.4811
19vactosertib2.4010
20gsk 10709162.208
21cyc 1162.087
22osi 0272.087
23osi 6321.795
24Crizotinib0.691
25Dasatinib0.691

About ACVR1B as a Drug Target

ACVR1B (activin A receptor type 1B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented ACVR1B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ACVR1B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.